Sebia completed the acquisition of ORGENTEC Diagnostika from Water Street Healthcare Partners.

Sebia, a provider of clinical protein electrophoresis equipment and reagents, completed the acquisition of ORGENTEC Diagnostika, a specialty diagnostics company, from Water Street Healthcare Partners, a strategic investor focused exclusively on healthcare. Financial terms were not disclosed. "Through this acquisition, we will be able to expand Sebia’s capabilities to provide high-value solutions to our customers and patients. ORGENTEC AROTEC and Corgenix have developed strong expertise in autoimmunity, infectious diseases and clinical trials and we see many Areas for collaboration in our respective R&D programs and benefits for our global commercial network development. I am very pleased to welcome ORGENTEC group associates to Sebia and look forward to a strong collaboration to accelerate innovation and global growth," Jean-Marc Chermette, Sebia President and CEO.